Sangamo BioSciences, Inc. (SGMO)
2012 Wedbush PacGrow Lifesciences Management Access Conference
August 14, 2012 9:10 AM ET
Edward Lanphier – CEO
Geoff Nichol – EVP, Research and Development
Liana Moussatos – Wedbush Securities
Okay. We’ll get started. I’m Liana Moussatos from Wedbush, and today we have the CEO of Sangamo, Edward Lanphier, who will give us a corporate presentation followed by Q&A. Edward?
Good morning. I don’t know why it is that West Coast companies draw the short straw and get the early morning talks, but I’m fully caffeinated and ready to go. Good morning, Liana. Thanks so much for including us in this year’s conference. In addition to myself, I’m joined here upfront by my colleague, Geoff Nichol, who is our EVP of Research and Development, and also in the audience, my colleague, Dr. Elizabeth Wolffe, Head of Corporate Communications.
My presentation today will contain forward-looking statements. I refer you to our Forms 10-K and 10-Q filed with the SEC for additional information. Before diving in to the presentation, Liana has asked that maybe I go through this relatively quickly. I won’t try and speak coherently in the morning here, but leaving time for questions and happy to do so.
So as we dive in, just to remind you, Sangamo is unique, unique in a very specific way, and that is our core technology provides an opportunity to engineer a naturally occurring class of DNA-binding proteins, the most common, the most abundant class or type of DNA-binding protein found on our planet, from humans all the way down to worms and flies and so on. These are called zinc finger DNA-binding proteins, and these are small, about 30 amino acids. They’re modular proteins that nature was able to use or engineer to bind to unique sequences of DNA as genomes became larger and larger.